Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rapamune · 3 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| Rapamune | DRUG | - |
| Rapamune® | DRUG | - |
| Rapamune® (Sirolimus) | DRUG | - |
| Tacrolimus | DRUG | - |
| Corticosteroids | DRUG | Perioperative |
Inclusion criteria: * Patients of African-American descent or patient with a history of multiple transplants and/or patients with a high panel reactive antibody lab test with a renal transplant from a cadaveric donor, a living unrelated donor or a living-related mismatched donor. * Age \>= 13 years...
Top 20 of 25 competitors
Rapamune is used for kidney transplantation, specifically in renal allograft recipients and patients with kidney disease. It is an immunosuppressant small molecule developed by Pfizer, Inc. (NYSE: PFE) to help prevent organ rejection in kidney transplant patients.
Rapamune works by inhibiting the mammalian target of rapamycin (mTOR), a key protein kinase that regulates cell growth and proliferation. By blocking mTOR, Rapamune suppresses the immune system's T-cell response, which helps prevent the rejection of transplanted kidneys in renal allograft recipients.
Rapamune is developed by Pfizer, Inc., a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. Pfizer is responsible for the research, development, and commercialization of this immunosuppressant medication for kidney transplant patients.
Rapamune is in Phase 3 clinical development for kidney transplantation and related kidney disease indications. It has completed multiple clinical trials, including Phase 3 studies, and remains an investigational drug in active clinical development for these uses.
Rapamune has been studied in several completed clinical trials, including NCT00248313, a Phase 3 study comparing cyclosporin dose reduction with elimination in kidney transplant recipients taking sirolimus, and NCT00470665, a Phase 3 study comparing sirolimus-based regimens in high-risk renal transplant recipients. These trials enrolled hundreds of patients.
Yes, Rapamune is the brand name for sirolimus, an immunosuppressant drug. In clinical trials, it is often referred to as sirolimus, and Rapamune is the proprietary name used by Pfizer. Both names refer to the same active pharmaceutical ingredient used in kidney transplantation.